[摘 要] 骨髓增生异常综合征（MDS）是一种起源于造血干细胞的髓系恶性肿瘤，其发病率逐年攀升。近年来，靶向特定抗原的嵌合抗原受体基因修饰T淋巴细胞（CAR-T细胞）疗法在血液肿瘤领域取得显著成功，为MDS的治疗开辟了新方向。推动CAR-T细胞疗法成功应用的关键在于寻找MDS特异性靶抗原。研究发现，CD44剪接变异体CD44v6在MDS患者早期红系无效造血中普遍高表达，提示其是极具潜力的治疗靶标。本综述系统梳理CD44v6调控MDS病理进程的研究新进展，重点解析靶向CD44v6的创新治疗策略（包括CAR-T细胞疗法）的临床转化价值，并探讨其在推动MDS精准个体化治疗中的应用前景。

[Abstract] Myelodysplastic syndromes (MDS) are a group of myeloid malignancies originating from hematopoietic stem cells, with an increasing incidence rate year by year. In recent years, chimeric antigen receptor gene-modified T lymphocyte (CAR-T cell) therapy targeting specific antigens has achieved remarkable success in the field of hematological tumors, opening up new directions for the treatment of MDS. The key to promoting the successful application of CAR-T cell therapy lies in finding MDS-specific target antigens. Studies have found that CD44 splice variant CD44v6 is generally highly expressed in early-stage ineffective erythropoiesis in MDS patients, suggesting it is a highly promising therapeutic target. This review systematically summarizes the new research progress on CD44v6 regulating the pathological process of MDS, focuses on analyzing the clinical translational value of innovative therapeutic strategies targeting CD44v6 (including CAR-T cell therapy), and explores its application prospects in promoting precision personalized treatment of MDS.

武汉市卫健委西医科研项目